CD47 and neoplasm: Seeking to address this, several studies have worked with mouse tumor resection models and demonstrated efficacy of biomaterials-based local delivery systems that can prolong the release of diverse immune agonists (e.g., TLR7/8, STING) or antibodies (e.g., anti-CD47), including for example a biodegradable hydrogel encasing these agents placed at the tumor resection site12,13.